AlloVir Inc. (ALVR) stock is currently on the rise in the current market after announcing an RMAT status by FDA for Posoleucel. ALVR stock values at $7.55, gaining more than 40% from the previous close. ALVR stock previously closed at $5.41 with a trading volume of around 259.70K shares.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Global Biotech Industry Dynamics
ALVR is a company that works in the research and development and marketing of off-the-shelf viral suppressive treatments (VSTs) to prevent and cure severe virus-associated disorders (SVADs). Patients with severely impaired immune systems may benefit from the company’s innovative cell treatments, which aim to rebuild their natural protection against life-threatening virus-associated disorders.
According to the World Economic Forum, the global biotechnology business was valued at $733 billion in 2020 and $793 billion in 2021. According to the estimations, the worldwide market size of the biotechnology sector would be valued at around $1.6 trillion in 2030, with a compound annual growth rate of 8.7% over the next decade.
ALVR: Approval by FDA for RMAT
The FDA has designated AlloVir’s primary experimental multi-virus-specific T cell treatment, posoleucel a Regenerative Medicine Advanced Therapy (RMAT) status, to protect clinically significant infections and illnesses from six deadly viruses. Following allogeneic hematopoietic cell transplantation, this virus usually affects adults. The FDA has now designated posoleucel as an RMAT for the third time, recognizing its transformational potential in treating immunocompromised allo-HCT patients.
The FDA previously approved Posoleucel to treat hemorrhagic cystitis induced by BKV in children and adults after allo-HCT and adenovirus infection after allo-HCT. This allows for early discussions on clinical trial design and other activities to hasten development and review. It is also approved in Europe to treat severe infections with AdV, BKV, CMV, EBV, and HHV-6.
The company is currently developing a treatment for the infections and diseases caused by deadly viruses. The RMAT status for their study could help them further test the treatment and reach a better conclusion.